Amneal Pharmaceuticals, Inc. Cash Flow Statement
AMRX / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Amneal Pharmaceuticals, Inc. generated $340M in operating cash flow and $270M in free cash flow in FY2025. Free cash flow margin was 8.9% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $72.1M | -$116.9M | $13.2M | -$270.6M | -$603.6M | -$19.7M | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $57.3M | - | $60.7M | - | $63.3M | $64.4M | $42.0M | $29.3M | - | $29.3M |
| Operating Cash Flow | $340.0M | $295.1M | $241.8M | $65.1M | $1.7M | $250.2M | $234.2M | $115.1M | $234.2M | $115.1M |
| Capital Expenditures | $70.1M | $51.9M | $47.7M | $46.4M | $47.2M | $83.1M | $94.8M | $122.8M | $94.8M | $122.8M |
| Free Cash Flow | $269.9M | $243.2M | $194.1M | $18.7M | -$45.5M | $167.1M | $139.4M | -$7.7M | $139.4M | -$7.7M |
| Share Buybacks | - | - | - | - | - | - | - | $5.0K | - | $5.0K |
| Dividends Paid | - | - | - | - | - | $183.0M | $375.3M | $200.6M | $375.3M | $200.6M |
| FCF Margin | 8.9% | 8.7% | 9.3% | 0.8% | -2.8% | 10.1% | 13.5% | -0.8% | 13.5% | -0.8% |